Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type
Press Release
SAN DIEGO, May 18, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care.
SAN DIEGO, May 18, 2022 /3BL Media/ - Illumina has been included for the first time on the 2022 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and governance (ESG) performance among the 1,000 largest U.S. public companies. Illumina ranked #62 overall, #6 within our industry, and #1 overall in the employee category.
First-of-its-kind partnership will identify drug targets and accelerate novel therapy development using genomics and artificial intelligence
Press Release
SAN DIEGO, May 5, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs. The partnership aims to leverage genomic tools and genetic knowledge to select programs with a higher probability of success in order to lower research and development costs and accelerate the approval of cutting-edge therapies.
Partnership aims to provide better understanding of common disease risk prediction through their Polygenic Risk Score (PRS) software suite
Article
By Susan Tousi Chief Commercial Officer at Illumina
Customers and our partners represent the heartbeat of Illumina. They help us advance our mission to improve human health through unlocking the power of the genome.
And as we enter further into the era of genomic medicine, personalized medicine must play a more integral role for every patient’s health.
Strategic Dx partnering allows for innovation and value at scale
Summary:
Collaboration aims to enable personalized, highly effective therapies for each tumor type and enable early detection through screening and monitoring tests.
Illumina data analytics platforms and collaborative lab services will enable more effective and efficient drug discovery by harnessing the power of genomics.
Article
Collaboration aims to enable personalized, highly effective therapies for each tumor type and enable early detection through screening and monitoring tests.
Illumina data analytics platforms and collaborative lab services will enable more effective and efficient drug discovery by harnessing the power of genomics.
Illumina’s advances in genetic sequencing are reshaping medicine. Genetic sequencing has now allowed cancer patients to find treatment options specific to their tumors, doctors to anticipate adverse drug reactions and personalize medicine, public health agencies around the world to track and detect new COVID variants, and patients with rare diseases to more easily identify and treat their illnesses.
Hannover Medical School study will evaluate the use of whole-genome sequencing to show positive impact of earlier diagnosis and treatment for children with suspected genetic disorders
Press Release
SAN DIEGO, April 25, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced an agreement with Germany's Hannover Medical School (Medizinische Hochschule Hannover (MHH)) to implement the use of whole-genome sequencing (WGS) in critically ill children suspected of having a genetic or rare disease.
Cambridge is unveiled as the launchpad for the biggest long-term initiative ever unveiled on this side of the Atlantic to get more youngsters involved in STEM careers – thanks to US genomics giant Illumina.
Illumina and Cambridge LaunchPad joined forces in an historic venture to take the DNA Day programme to UK schools for the first time. Cambridge was chosen for the launch as the founding cradle of DNA discovery and genomics advancements.
Two years into the pandemic that has killed millions and shaken the global economy, the world still lacks a unified effort to detect and fight future outbreaks using genetic tools, said Illumina Inc. Chief Executive Officer Francis deSouza.
How genomics provided critical answers—and in record time—to transform outcomes for a newborn and his family
Article
In June 2019, Christina and Daniel Kettler were barely home from the hospital with their newborn son when they received an urgent phone call. They needed to rush back immediately: A routine screening, called the heel stick test, had revealed that Fitz, their firstborn baby, had Severe Combined Immunodeficiency (SCID). SCID is a rare condition also known as “bubble boy disease.”
